Solara Active Pharma Sciences (NSE:SOLARAPP1) Beneish M-Score: -2.36 (As of Jul. 03, 2026)


NSE:SOLARAPP1 Solara Active Pharma Sciences Ltd NSE:SOLARAPP1
67 GF Score
Price ₹267.45
GF Value ₹263.62
! 3 Warning Signs
View Full Analysis

What is Solara Active Pharma Sciences Beneish M-Score?

Solara Active Pharma Sciences NSE:SOLARAPP1 67 Beneish M-Score is -2.36 as of Jul. 03, 2026. GuruFocus rates NSE:SOLARAPP1 with a GF Score™ of 67/100 and a GF Value™ of ₹263.62. The stock has 3 warning signs investors should review. Among 909 Drug Manufacturers companies, Solara Active Pharma Sciences ranks worse than 60.18% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.36 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Solara Active Pharma Sciences's Beneish M-Score or its related term are showing as below:

NSE:SOLARAPP1' s Beneish M-Score Range Over the Past 10 Years
Min: -4.18   Med: -2.62   Max: -1.8
Current: -2.36

During the past 10 years, the highest Beneish M-Score of Solara Active Pharma Sciences was -1.80. The lowest was -4.18. And the median was -2.62.


Solara Active Pharma Sciences Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Solara Active Pharma Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solara Active Pharma Sciences Beneish M-Score Chart

Solara Active Pharma Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.10 -2.62 -4.18 -3.06 -2.36

Solara Active Pharma Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.06 0.00 0.00 0.00 -2.36

NSE:SOLARAPP1 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solara Active Pharma Sciences Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Solara Active Pharma Sciences's Beneish M-Score falls into.


NSE:SOLARAPP1
67GF Score
Solara Active Pharma Sciences Ltd NSE:SOLARAPP1
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solara Active Pharma Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Solara Active Pharma Sciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2139+0.528 * 1.0241+0.404 * 0.9384+0.892 * 1.0664+0.115 * 0.9788
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * -0.06873-0.327 * 0.9104
=-2.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹4,388 Mil.
Revenue was ₹13,690 Mil.
Gross Profit was ₹6,845 Mil.
Total Current Assets was ₹8,581 Mil.
Total Assets was ₹23,326 Mil.
Property, Plant and Equipment(Net PPE) was ₹10,552 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹997 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹8,939 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,297 Mil.
Net Income was ₹-74 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹1,529 Mil.
Total Receivables was ₹3,390 Mil.
Revenue was ₹12,838 Mil.
Gross Profit was ₹6,574 Mil.
Total Current Assets was ₹7,287 Mil.
Total Assets was ₹22,318 Mil.
Property, Plant and Equipment(Net PPE) was ₹10,756 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹993 Mil.
Selling, General, & Admin. Expense(SGA) was ₹493 Mil.
Total Current Liabilities was ₹9,441 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,316 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4387.5 / 13689.8) / (3389.5 / 12837.6)
=0.320494 / 0.264029
=1.2139

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6573.5 / 12837.6) / (6844.7 / 13689.8)
=0.512051 / 0.499985
=1.0241

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (8581 + 10552) / 23325.9) / (1 - (7287.3 + 10756.1) / 22318.4)
=0.179753 / 0.191546
=0.9384

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=13689.8 / 12837.6
=1.0664

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(992.5 / (992.5 + 10756.1)) / (996.8 / (996.8 + 10552))
=0.084478 / 0.086312
=0.9788

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 13689.8) / (492.9 / 12837.6)
=0 / 0.038395
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1296.6 + 8939.1) / 23325.9) / ((1316.3 + 9441.1) / 22318.4)
=0.438813 / 0.481997
=0.9104

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-74.1 - 0 - 1529.1) / 23325.9
=-0.06873

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Solara Active Pharma Sciences has a M-score of -2.36 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.36 mean?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a Beneish M-Score of -2.36 as of Jul. 03, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Solara Active Pharma Sciences and its competitors. According to the industry distribution chart, Solara Active Pharma Sciences ranks #547 out of 909 companies in the Drug Manufacturers industry, placing it in the top 60.2%.
Is Solara Active Pharma Sciences' Beneish M-Score too high?
Solara Active Pharma Sciences' current Beneish M-Score is -2.36. Based on the distribution chart, Solara Active Pharma Sciences ranks #547 out of 909 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Solara Active Pharma Sciences has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Solara Active Pharma Sciences ranks #547 out of 909 companies for Beneish M-Score. This places Solara Active Pharma Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Solara Active Pharma Sciences and its competitors. Solara Active Pharma Sciences's current Beneish M-Score is -2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a current Beneish M-Score of -2.36. The stock's GF Value™ is ₹263.62, compared to a current price of ₹267.45 — trading 1.5% above its estimated fair value. The current Beneish M-Score is -2.36. Solara Active Pharma Sciences' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Solara Active Pharma Sciences (NSE:SOLARAPP1), the current Beneish M-Score is -2.36 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Solara Active Pharma Sciences (NSE:SOLARAPP1) Overvalued in 2026?

Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be overvalued. The current stock price of ₹267.45 is trading 1.5% above its estimated GF Value™ of ₹263.62.

Key valuation signals for NSE:SOLARAPP1:

  • Beneish M-Score: -2.36
  • GF Value™: ₹263.62 vs. price of ₹267.45 (1.5% above fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the NSE:SOLARAPP1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Solara Active Pharma Sciences Business Description

Other Exchanges SOLARA:India541540:India
Address Phase II - CSIR Road, Module No. 601, 602, 603, Ticel Bio Park, Taramani, Chennai, TN, IND, 600113
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
67GF Score

Get the complete analysis for NSE:SOLARAPP1

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹267.45
Price
₹263.62
GF Value